RA Capital Management

Selected news for the capital firm - RA Capital Management, collected since 11/2017. Recent stories appear in FierceBiotech. This capital firm shares healthcare news with Infectious Disease, OrbiMed, Biopharma, Oncology and dozens of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
4/19/2021 Adagio adds $336M for pivotal tests of drug with potential to beat Covid variants MedCity News ... to drive the spread of the novel coronavirus, has raised $336 million to conduct a pivotal study of its lead experimental treatment.The new capital, a Series C round of funding, was led by RA Capital Management . It comes nine months after Waltham, Massachusetts-based Adagio launched with science from Adimab, a company that discovers and engineers antibodies. It’s led by co-founder and CEO Tillman Gerngross, the serial ...
4/19/2021 Adagio raises a monster $336M round for bespoke COVID-19 drug battle FierceBiotech ... is found on multiple viruses, including SARS-CoV-1 and some coronaviruses circulating in bats. It now has an extra $336 million in the bank for its clinical plans, with the cash coming from RA Capital Management , which led the round, with help from a host of new investors including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest and another leading healthcare investor. Existing investors Fidelity Management & Research Company ...
4/19/2021 Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19 | Business Wire Business Wire WALTHAM, Mass.--( BUSINESS WIRE )--Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the completion of a $336 million Series C financing led by RA Capital Management , with participation from new investors, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor. Existing investors Fidelity Management & Research Company, LLC, OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners ...
4/19/2021 Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19 Yahoo News ... Jane Henderson as Chief Financial OfficerAdagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the completion of a $336 million Series C financing led by RA Capital Management , with participation from new investors, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor. Existing investors Fidelity Management & Research Company, LLC, OrbiMed, Polaris Partners, Mithril, GV, Population ...
4/15/2021 Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics | Business Wire Business Wire Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics Funding round led by RA Capital Management with Lightstone Ventures and DHVC follows a Seed round led by SV Health Investors Proceeds to be used to advance lead programs in neurodegeneration and cancer Alchemab applies extremely high-throughput antibody sequencing and deep-learning to well-defined patient cohorts to identify naturally-occuring ...
4/15/2021 Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics Yahoo News Funding round led by RA Capital Management with Lightstone Ventures and DHVC follows a Seed round led by SV Health InvestorsProceeds to be used to advance lead programs in neurodegeneration and cancerAlchemab applies extremely high-throughput antibody sequencing and deep-learning to well-defined patient cohorts to identify naturally-occuring protective antibodies in people who are resilient to diseaseAlchemab Therapeutics, a biotech company developing novel products for ...
4/15/2021 The Ridgway Record ridgwayrecord.com ... with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.The international investment syndicate is led by RA Capital Management , with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company was created by SV Health Investors who led the Seed round in 2019 ...
4/15/2021 malvern-online.com ... with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.The international investment syndicate is led by RA Capital Management , with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company was created by SV Health Investors who led the Seed round in 2019 ...
4/15/2021 Alchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics Business Wire ... with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.The international investment syndicate is led by RA Capital Management , with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company was created by SV Health Investors who led the Seed round in 2019 ...
4/15/2021 Alchemab raises 60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics financialbuzz.com ... with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.The international investment syndicate is led by RA Capital Management , with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund. The company was created by SV Health Investors who led the Seed round in 2019 ...
4/15/2021 Alchemab Raises $82 Million to Advance Antibody Therapeutics in Neurodegeneration and Cancer globalgenes.org Rare Daily Staff Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, said it closed an $82 million (£60 million) series A financing round. RA Capital Management led the financing, with participation by an international syndicate that included Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors, and the Dementia Discovery Fund. The company was ...
4/12/2021 Antios Therapeutics Raises $96 Million in a Series B Financing vcaonline.com Antios Therapeutics Raises $96 Million in a Series B Financing Funding will support the Phase 2 clinical program of ATI-2173 in HBV Soleus Capital led the round with new major investors RA Capital Management , Adage Capital Management LP, Pontifax and Aisling Capital as well as Altium Capital, Amzak Health, Granite Point Capital Management, LP, and LifeSci Venture Partners and participating existing investors Lumira Ventures, Cam Capital, Delos Capital, Domain ...
4/9/2021 Werewolf Therapeutics files for IPO - MarketWatch MarketWatch ... an initial public offering.The Cambridge, Mass., company has applied for a Nasdaq Global Market listing under symbol HOWL.Werewolf said in January that it completed its $72 million Series B financing, led by RA Capital Management . According to the filing, RA Capital has a 11.25% stake. MPM Capital owns 20.75%, and an oncology fund that MPM raised in partnership with UBS Group AG holds 11.56%.In February, Werewolf named ...
4/8/2021 Liquid biopsy maker Nucleix rakes in $55M to develop blood tests to detect lung cancer early FierceBiotech It’s full steam ahead for Nucleix’s blood test for lung cancer detection, thanks to an influx of cash in the Israeli company’s latest round of funding.The liquid biopsy maker closed its oversubscribed $55 million financing on April 7. RA Capital Management led the round, with additional participation from new and existing investors including BlackRock-managed funds and accounts, Lilly Asia Ventures, OrbiMed and more.The financial ...
4/8/2021 Ventus Therapeutics Closes $100 Million Series B Financing | Business Wire Business Wire WALTHAM, Mass. & MONTREAL--( BUSINESS WIRE )--Ventus Therapeutics, Inc., a biotechnology company utilizing rational structure-based drug design to discover small-molecule medicines for high value and elusive targets, today announced a $100 million Series B financing led by RA Capital Management with participation from a select syndicate including BVF Partners L.P., Casdin Capital, Cormorant Asset Management, Fonds de solidarité FTQ, and Alexandria Venture Investments. Founding investor Versant Ventures also participated ...
4/8/2021 Ventus Therapeutics Closes $100 Million Series B Financing Yahoo News ... targetsVentus Therapeutics, Inc., a biotechnology company utilizing rational structure-based drug design to discover small-molecule medicines for high value and elusive targets, today announced a $100 million Series B financing led by RA Capital Management with participation from a select syndicate including BVF Partners L.P., Casdin Capital, Cormorant Asset Management, Fonds de solidarité FTQ, and Alexandria Venture Investments. Founding investor Versant Ventures also participated in the round, as ...
4/8/2021 Ventus Therapeutics Raises $100M in Series B Financing finsmes.com ... and Montreal, Canada-based biotechnology company utilizing rational structure-based drug design to discover small-molecule medicines for high value and elusive targets, raised $100m in Series B financing.The round was led by RA Capital Management with participation from a select syndicate including BVF Partners L.P., Casdin Capital, Cormorant Asset Management, Fonds de solidarité FTQ, and Alexandria Venture Investments. Founding investor Versant Ventures also participated in the round, as ...
4/8/2021 Ventus Therapeutics Closes $100 Million Series B Financing vcaonline.com ... 2021-- Ventus Therapeutics, Inc., a biotechnology company utilizing rational structure-based drug design to discover small-molecule medicines for high value and elusive targets, today announced a $100 million Series B financing led by RA Capital Management with participation from a select syndicate including BVF Partners L.P., Casdin Capital, Cormorant Asset Management, Fonds de solidarité FTQ, and Alexandria Venture Investments. Founding investor Versant Ventures also participated in the round, as ...
4/8/2021 Ventus Therapeutics Closes $100 Million Series B Financing financialbuzz.com Ventus Therapeutics, Inc., a biotechnology company utilizing rational structure-based drug design to discover small-molecule medicines for high value and elusive targets, today announced a $100 million Series B financing led by RA Capital Management with participation from a select syndicate including BVF Partners L.P., Casdin Capital, Cormorant Asset Management, Fonds de solidarité FTQ, and Alexandria Venture Investments. Founding investor Versant Ventures also participated in the round, as did ...
4/8/2021 Werewolf Therapeutics files for IPO - MarketWatch MarketWatch ... an initial public offering.The Cambridge, Mass., company has applied for a Nasdaq Global Market listing under symbol HOWL.Werewolf said in January that it completed its $72 million Series B financing, led by RA Capital Management . According to the filing, RA Capital has a 11.25% stake. MPM Capital owns 20.75%, and an oncology fund that MPM raised in partnership with UBS Group AG holds 11.56%.In February, Werewolf named ...